This study aims to investigate the effectiveness and safety of retatrutide, a new diabetes medication) at doses of 4 mg, 9 mg, or 12 mg that will be taken as a weekly injection for about 1 year, compared to a placebo. A participant's change in HbA1c level will be primary outcome of interest. We are seeking participants with type 2 diabetes that has affected kidney function and are currently taking long-acting insulin with metformin and/or a SGLT2 inhibitor.
The study involves 21 study visits over the course of 1 year with a safety follow up visit following visit 21. Of the 21 visits, 5 of the visits will occur via telehealth and most visits are expected to last approximately one hour, but some may take longer. Visits will include completion of assessments covering your medical history and current medication regimen, surveys, lab draws, vital signs, measurement of height, weight, and waist circumference. At a few visits, you may also receive a physical exam and an ECG. Completion of blood sugar diaries, hypoglycemia diaries, and wearing a continuous glucose monitor at certain times throughout the study are also required. If you choose to participate, we will ask that you are able attend all in-person visits at 100 Eastowne Drive in Chapel Hill.
$84-$420 per visit, travel reimbursement
UNC Eastowne Medical Office Building
100 Eastowne Dr, Chapel Hill, NC 27514, USA
Klara Klein
Medicine-Endocrinology
Clinical or Medical
Interventional
Chronic Conditions
Diabetes
Kidneys and Liver
24-0423